Bachem Holding AG (0QND.L)

CHF 51.28

(1.5%)

EBITDA Summary of Bachem Holding AG

  • Bachem Holding AG's latest annual EBITDA in 2023 was 163.27 Million CHF , up 3.94% from previous year.
  • Bachem Holding AG's latest quarterly EBITDA in 2024 Q2 was 55.45 Million CHF , down 0.0% from previous quarter.
  • Bachem Holding AG reported an annual EBITDA of 157.07 Million CHF in 2022, up 2.02% from previous year.
  • Bachem Holding AG reported an annual EBITDA of 156.46 Million CHF in 2021, up 28.54% from previous year.
  • Bachem Holding AG reported a quarterly EBITDA of 113.83 Million CHF for 2023 Q4, down 0.0% from previous quarter.
  • Bachem Holding AG reported a quarterly EBITDA of 52.08 Million CHF for 2023 Q2, down 0.0% from previous quarter.

Annual EBITDA Chart of Bachem Holding AG (2023 - 2002)

Historical Annual EBITDA of Bachem Holding AG (2023 - 2002)

Year EBITDA EBITDA Growth
2023 163.27 Million CHF 3.94%
2022 157.07 Million CHF 2.02%
2021 156.46 Million CHF 28.54%
2020 121.72 Million CHF 40.99%
2019 86.33 Million CHF 14.54%
2018 78.31 Million CHF 9.31%
2017 69.73 Million CHF 6.51%
2016 65.96 Million CHF 15.03%
2015 56.28 Million CHF 8.8%
2014 51.72 Million CHF 10.34%
2013 47.6 Million CHF 11.03%
2012 42.51 Million CHF 33.3%
2011 32.79 Million CHF -38.3%
2010 50.23 Million CHF -22.39%
2009 61.67 Million CHF -20.07%
2008 82.77 Million CHF -7.93%
2007 84.26 Million CHF 36.97%
2006 69.43 Million CHF 18.59%
2005 55.34 Million CHF 1.47%
2004 54.54 Million CHF -10.37%
2003 60.85 Million CHF -1.16%
2002 61.56 Million CHF 0.0%

Peer EBITDA Comparison of Bachem Holding AG

Name EBITDA EBITDA Difference
Relief Therapeutics Holding AG -108.2 Million CHF 250.899%
Tecan Group AG 205.57 Million CHF 20.576%
Santhera Pharmaceuticals Holding AG 79.17 Million CHF -106.224%
Basilea Pharmaceutica AG 29.49 Million CHF -453.572%
Siegfried Holding AG 241.21 Million CHF 32.312%
Molecular Partners AG -59.51 Million CHF 374.344%